Clinical observation of Qingfei Xiaoyan Pill in treatment of lung phlegm heat syndrome in children with acute bronchitis
10.7501/j.issn.0253-2670.2016.10.019
- Author:
Si-Yuan HU
1
Author Information
1. The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
Children with acute bronchitis;
Lung phlegm heat syndrome;
Multi-center clinical study;
Qingfei Xiaoyan Pill;
Xiaoer Feire Kechuan Oral Liquid
- From:
Chinese Traditional and Herbal Drugs
2016;47(10):1746-1749
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and safety of Qingfei Xiaoyan Pill (QXP) in the treatment of lung phlegm heat syndrome in children with acute bronchitis. Methods: Stratified random, open, parallel-group controlled, and multi-center clinical studies were applied. Totally 96 patients suffering from Xiao'er acute bronchitis were randomly divided into treatment group and the control group according to 2:1 ratio. The patients in treatment group were given QXP for application while the patients in control group were given Xiaoer Feire Kechuan Oral Liquid for application, 5 d in total. Results: The curative rates of treatment and control groups in disease efficacy were 76.92% and 50.00%, and the curative rates of both groups in traditional Chinese medicine syndrome effect were 78.85% and 60.76%. These of treatment group were better than those of control group, and there were significant differences between the two groups (P < 0.05). Except ropy sputum, compared with same group before treatment, there were no significant differences between the two groups in single syndrome curative effect (P > 0.05). Conclusion: QXP has a definite effect on lung phlegm heat syndrome in children with acute bronchitis with good safety and is better than Xiaoer Feire Kechuan Oral Liquid.
